Explore research findings and treatment updated from the past month


** Epilepsy Research News: August 2020
------------------------------------------------------------
This month’s research news includes two new approaches for developing epilepsy treatments. One is a new antiseizure ([link removed]) drug target and the other creates a completely novel type of antiseizure drug ([link removed]) based on a vitamin.

Recent studies also broadened our understanding of developmental outcomes in people with epilepsy and possible causes of intellectual delays in some individuals. A research team demonstrated that there is no difference in the developmental or behavioral outcomes of children who have febrile seizures following vaccination ([link removed]) compared to children who do not have these seizures. In addition, data from another study shows that two specific genetic mutations ([link removed]) which cause the development of epilepsy, as well as intellectual disability affect the same brain protein in the same way.

In addition, research suggests that many people with epilepsy living in rural areas of China ([link removed]) could become seizure-free with expanded access to routine neurosurgery. Finally, in the US the FDA has approved Epidiolex ([link removed]) ^® (cannabidiol) oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients age 1 and older. Patients and their families can read the full FDA statement here ([link removed]) .

Summaries of these research discoveries and news highlights are below.

Research Discoveries
* Novel Target for Antiseizure Drugs: An international study, featuring the work of former CURE grantee Dr. David Henshall, discovered that a small set of molecules called microRNAs, which control gene activity in the brain, are elevated in epilepsy. The team created inhibitors of these microRNAs, and when three of these inhibitors were combined, they were found to stop seizures in laboratory tests. Learn more ([link removed])
* Novel Antiseizure Drug: Researchers report that a novel vitamin K-based therapy has proved effective in reducing seizures in mouse models of medication-resistant seizures. Learn more ([link removed])
* Vaccination and Seizures: A study demonstrated that there is no difference in developmental and behavioral outcomes for children who have febrile seizures after vaccination, children who have febrile seizures not associated with vaccination, and children who have never had a seizure. Learn more ([link removed])
* Intellectual Disability and Epilepsy: Two mutations identified in people with developmental and epileptic brain disease can be traced back to the same brain protein known as TRPM3, which is responsible for sensing heat and pain. Researchers have determined how both mutations independently make the protein overly active and extremely sensitive to stimulation, taking the first step towards unraveling what causes the symptoms in patients with these mutations. Learn more ([link removed])
* Neurosurgery in China: A study researching the causes and outcomes of epilepsy in people who live in rural China found that at least one million individuals could be candidates for a surgical procedure that may leave them seizure-free. Learn more ([link removed])
* New Therapy for Tuberous Sclerosis Complex (TSC): The FDA recently approved Epidiolex® (cannabidiol) oral solution for the treatment of seizures associated with TSC in patients 1 year of age and older. Epidiolex had previously been approved for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome. Learn more ([link removed])

Join leading epilepsy experts as they discuss the current research landscape during Unite to CURE Epilepsy ([link removed]) . This live streamed evening showcasing tenacity, discovery, and hope will also feature inspirational stories from the CURE community and special performers, including Eric Church.
Our mission is to find a cure for epilepsy, by promoting and funding patient-focused research. CURE is a non-profit 501(c)(3) tax-exempt organization. Our tax identification number is 36-4253176.
[link removed]
[link removed]
[link removed]
[link removed]-
[link removed]
[link removed]

============================================================
Copyright © 2020 Citizens United for Research in Epilepsy (CURE), All rights reserved.
In the past you provided Citizens United for Research in Epilepsy your email address. Occasionally, you will receive updates from CURE about epilepsy research and news.

Our mailing address is:
Citizens United for Research in Epilepsy (CURE)
420 Wabash Ave, Ste 650
Chicago, IL 60611
USA
Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.

This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
Citizens United for Research in Epilepsy (CURE) . 420 Wabash Ave, Ste 650 . Chicago, IL 60611 . USA